Literature DB >> 20683396

Chemotherapy induces macrophage chemoattractant protein-1 production in ovarian cancer.

Melissa A Geller1, Tri M Bui-Nguyen, Lisa M Rogers, Sundaram Ramakrishnan.   

Abstract

OBJECTIVES: Tumor infiltrating macrophages play an important role in tumor progression. Macrophage chemoattractant protein-1 (MCP-1) is one of the major chemokines responsible for inducing macrophage migration. Our objective was to investigate chemotherapy-induced modulation of MCP-1 in ovarian cancer by investigating macrophage infiltration, tumor vascularity, and MCP-1 expression after chemotherapy exposure.
METHODS: MA-148 ovarian cancer cells were treated with paclitaxel (43 pg/mL) and carboplatin (5 microg/mL) alone or in combination. Reverse transcription-polymerase chain reaction determined MCP-1 transcript levels and enzyme-linked immunosorbent assay evaluated MCP-1 protein production at multiple time points. The effect of kinase inhibitors on MCP-1 expression was investigated. In vivo MCP-1 production was examined in tumor-bearing mice and immunohistochemistry with fluorescein isothiocyanate conjugated anti-mouse F4/80 antibody, phycoerythrin-anti-CD31, and terminal deoxynucleotide transferase dUTP nick-end labeling assay were performed.
RESULTS: Macrophage chemoattractant protein-1 transcript levels were up-regulated in MA-148 after treatment with paclitaxel and carboplatin individually and in combination. The greatest elevation was seen with combination therapy: 2.5-fold increase in the MCP-1 protein levels from baseline (P = 0.011) with the mitogen-activated protein kinase and janus kinases/signal transducers and activators of transcription pathways appearing to be involved in the regulation of MCP-1 production. In vivo mouse studies confirmed increased MCP-1 production after chemotherapy; however, there was no significant difference in macrophage, apoptosis, or vessel density.
CONCLUSIONS: Macrophage chemoattractant protein-1 is up-regulated in ovarian cancer after chemotherapy in vitro and in vivo. Whether MCP-1 production is increased because of a stress-induced response or a scavenger response promoting macrophage infiltration remains unknown. Chemotherapy induction of MCP-1 in ovarian cancer suggests this chemokine plays an important role in the immune response occurring after chemotherapy exposure.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20683396     DOI: 10.1111/IGC.0b013e3181e5c442

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  15 in total

Review 1.  The secret ally: immunostimulation by anticancer drugs.

Authors:  Lorenzo Galluzzi; Laura Senovilla; Laurence Zitvogel; Guido Kroemer
Journal:  Nat Rev Drug Discov       Date:  2012-02-03       Impact factor: 84.694

2.  The Cancer Chemotherapeutic Paclitaxel Increases Human and Rodent Sensory Neuron Responses to TRPV1 by Activation of TLR4.

Authors:  Yan Li; Pavel Adamek; Haijun Zhang; Claudio Esteves Tatsui; Laurence D Rhines; Petra Mrozkova; Qin Li; Alyssa K Kosturakis; Ryan M Cassidy; Daniel S Harrison; Juan P Cata; Kenneth Sapire; Hongmei Zhang; Ross M Kennamer-Chapman; Abdul Basit Jawad; Andre Ghetti; Jiusheng Yan; Jiri Palecek; Patrick M Dougherty
Journal:  J Neurosci       Date:  2015-09-30       Impact factor: 6.167

3.  Cytokine-induced memory-like natural killer cells have enhanced function, proliferation, and in vivo expansion against ovarian cancer cells.

Authors:  Locke D Uppendahl; Martin Felices; Laura Bendzick; Caitlin Ryan; Behiye Kodal; Peter Hinderlie; Kristin L M Boylan; Amy P N Skubitz; Jeffrey S Miller; Melissa A Geller
Journal:  Gynecol Oncol       Date:  2019-01-15       Impact factor: 5.482

Review 4.  Vaccines for established cancer: overcoming the challenges posed by immune evasion.

Authors:  Sjoerd H van der Burg; Ramon Arens; Ferry Ossendorp; Thorbald van Hall; Cornelis J M Melief
Journal:  Nat Rev Cancer       Date:  2016-03-11       Impact factor: 60.716

5.  IL-15 super-agonist (ALT-803) enhances natural killer (NK) cell function against ovarian cancer.

Authors:  M Felices; S Chu; B Kodal; L Bendzick; C Ryan; A J Lenvik; K L M Boylan; H C Wong; A P N Skubitz; J S Miller; M A Geller
Journal:  Gynecol Oncol       Date:  2017-02-22       Impact factor: 5.482

6.  Investigation of the Mechanism of Impaired Skin Barrier Function in Dogs With Malignant Tumors.

Authors:  Migyeong Geum; Ha-Jung Kim
Journal:  In Vivo       Date:  2022 Mar-Apr       Impact factor: 2.155

7.  Dorsal Root Ganglion Infiltration by Macrophages Contributes to Paclitaxel Chemotherapy-Induced Peripheral Neuropathy.

Authors:  Hongmei Zhang; Yan Li; Marianna de Carvalho-Barbosa; Annemieke Kavelaars; Cobi J Heijnen; Phillip J Albrecht; Patrick M Dougherty
Journal:  J Pain       Date:  2016-03-12       Impact factor: 5.820

Review 8.  Tumor-Associated Macrophages in Human Breast, Colorectal, Lung, Ovarian and Prostate Cancers.

Authors:  Irina Larionova; Gulnara Tuguzbaeva; Anastasia Ponomaryova; Marina Stakheyeva; Nadezhda Cherdyntseva; Valentin Pavlov; Evgeniy Choinzonov; Julia Kzhyshkowska
Journal:  Front Oncol       Date:  2020-10-22       Impact factor: 6.244

9.  Immunosuppressive parameters in serum of ovarian cancer patients change during the disease course.

Authors:  An Coosemans; Judit Decoene; Thaïs Baert; Annouschka Laenen; Ahmad Kasran; Tina Verschuere; Sven Seys; Ignace Vergote
Journal:  Oncoimmunology       Date:  2015-12-21       Impact factor: 8.110

Review 10.  Crosstalk Between PD-1/PD-L1 Blockade and Its Combinatorial Therapies in Tumor Immune Microenvironment: A Focus on HNSCC.

Authors:  Weimin Lin; Miao Chen; Le Hong; Hang Zhao; Qianming Chen
Journal:  Front Oncol       Date:  2018-11-21       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.